791 related articles for article (PubMed ID: 23256501)
21. Refractoriness to the treatment of sodium stibogluconate in Indian kala-azar field isolates persist in in vitro and in vivo experimental models.
Dube A; Singh N; Sundar S; Singh N
Parasitol Res; 2005 Jun; 96(4):216-23. PubMed ID: 15868188
[TBL] [Abstract][Full Text] [Related]
22. Comment on: leishmaniasis: an update of current pharmacotherapy.
Arya SC; Agarwal N
Expert Opin Pharmacother; 2013 Jun; 14(9):1275-6. PubMed ID: 23621855
[No Abstract] [Full Text] [Related]
23. Using focused pharmacovigilance for ensuring patient safety against antileishmanial drugs in Bangladesh's National Kala-azar Elimination Programme.
Hossain MS; Kumar A; Hossain AFMA; Mahshin M; Sharma A; Hossain MA; Sharma V; Haque R; Shamsuzzaman AKM; Maruf S; Ghosh P; Ahuja V; Mondal D
Infect Dis Poverty; 2018 Aug; 7(1):80. PubMed ID: 30099967
[TBL] [Abstract][Full Text] [Related]
24. Magnitude of unresponsiveness to sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar.
Das VN; Ranjan A; Bimal S; Siddique NA; Pandey K; Kumar N; Verma N; Singh VP; Sinha PK; Bhattacharya SK
Natl Med J India; 2005; 18(3):131-3. PubMed ID: 16130613
[TBL] [Abstract][Full Text] [Related]
25. [Canine leishmaniasis: evolution of the chemotherapeutic protocols].
Oliva G; Foglia Manzillo V; Pagano A
Parassitologia; 2004 Jun; 46(1-2):231-4. PubMed ID: 15305724
[TBL] [Abstract][Full Text] [Related]
26. Recent advances in the treatment of visceral leishmaniasis.
Davidson RN; Croft SL
Trans R Soc Trop Med Hyg; 1993; 87(2):130-1, 141. PubMed ID: 8393221
[No Abstract] [Full Text] [Related]
27. Evaluating drug resistance in visceral leishmaniasis: the challenges.
Hendrickx S; Guerin PJ; Caljon G; Croft SL; Maes L
Parasitology; 2018 Apr; 145(4):453-463. PubMed ID: 27866478
[TBL] [Abstract][Full Text] [Related]
28. Current diagnosis and treatment of visceral leishmaniasis.
Mondal S; Bhattacharya P; Ali N
Expert Rev Anti Infect Ther; 2010 Aug; 8(8):919-44. PubMed ID: 20695748
[TBL] [Abstract][Full Text] [Related]
29. Treatment of visceral leishmaniasis (kala-azar): a decade of progress and future approaches.
Murray HW
Int J Infect Dis; 2000; 4(3):158-77. PubMed ID: 11179920
[TBL] [Abstract][Full Text] [Related]
30. Successful treatment of post-kala-azar dermal leishmaniasis (PKDL) in a HIV infected patient with multiple relapsing leishmaniasis from Western Europe.
Rihl M; Stoll M; Ulbricht K; Bange FC; Schmidt RE
J Infect; 2006 Jul; 53(1):e25-7. PubMed ID: 16274744
[TBL] [Abstract][Full Text] [Related]
31. [Liposomal amphotericin B as treatment for visceral leishmaniasis in Europe, 2009].
Rosenthal E; Delaunay P; Jeandel PY; Haas H; Pomares-Estran C; Marty P
Med Mal Infect; 2009 Oct; 39(10):741-4. PubMed ID: 19783391
[TBL] [Abstract][Full Text] [Related]
32. Combination Therapy Against Indian Visceral Leishmaniasis with Liposomal Amphotericin B (Fungisome
Goswami RP; Rahman M; Das S; Tripathi SK; Goswami RP
Am J Trop Med Hyg; 2020 Jul; 103(1):308-314. PubMed ID: 32394874
[TBL] [Abstract][Full Text] [Related]
33. [Change in human visceral leishmaniasis treatment in Italy: retrospective study of 630 patients].
Gradoni L; Gramiccia M; Scalone A
Parassitologia; 2004 Jun; 46(1-2):199-201. PubMed ID: 15305716
[TBL] [Abstract][Full Text] [Related]
34. Current treatment approaches to leishmaniasis.
Berman J
Curr Opin Infect Dis; 2003 Oct; 16(5):397-401. PubMed ID: 14501991
[TBL] [Abstract][Full Text] [Related]
35. Comparison of treatment regimens of kala-azar based on culture & sensitivity of amastigotes to sodium antimony gluconate.
Thakur CP; Thakur S; Narayan S; Sinha A
Indian J Med Res; 2008 Jun; 127(6):582-8. PubMed ID: 18765878
[TBL] [Abstract][Full Text] [Related]
36. [A case of antimony resistant kala-azar cured with amphotericin B].
Chen SB; Yang CM; Zhang CJ
Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi; 2007 Jun; 25(3):inside front page. PubMed ID: 18038767
[No Abstract] [Full Text] [Related]
37. Challenges in the management of visceral leishmaniasis.
Sundar S; Kumar A
Indian Pediatr; 2005 Jun; 42(6):523-6. PubMed ID: 15995268
[No Abstract] [Full Text] [Related]
38. A male preponderance in patients with Indian post kala-azar dermal leishmaniasis is associated with increased circulating levels of testosterone.
Mukhopadhyay D; Mukherjee S; Ghosh S; Roy S; Saha B; Das NK; Chatterjee M
Int J Dermatol; 2016 May; 55(5):e250-5. PubMed ID: 26536363
[TBL] [Abstract][Full Text] [Related]
39. Experience with miltefosine for persistent or relapsing visceral leishmaniasis in solid organ transplant recipients: A case series from Spain.
Pérez-Jacoiste Asín MA; Carrasco-Antón N; Fernández-Ruiz M; San Juan R; Alonso-Moralejo R; González E; Andrés A; López-Medrano F; Aguado JM
Transpl Infect Dis; 2017 Feb; 19(1):. PubMed ID: 27768239
[TBL] [Abstract][Full Text] [Related]
40. Activities of hexadecylphosphocholine (miltefosine), AmBisome, and sodium stibogluconate (Pentostam) against Leishmania donovani in immunodeficient scid mice.
Escobar P; Yardley V; Croft SL
Antimicrob Agents Chemother; 2001 Jun; 45(6):1872-5. PubMed ID: 11353640
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
